timothy sykes logo
Tenet Healthcare Stock Jumps After Big Earnings Beat And Buyback Boost Thumbnail

Tenet Healthcare Stock Jumps After Big Earnings Beat And Buyback Boost

JACK KELLOGGUPDATED JUL. 24, 2026, 4:09 PM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Tenet Healthcare Corporation stocks have been trading up by 17.55 percent following strong earnings and improved hospital admission trends.

What Traders Need To Know

  • Net income nearly tripled in Q2 2026 and adjusted EPS jumped 52%, powered by stronger same-facility revenue, better hospital margins, and solid ambulatory growth.
  • Q2 adjusted EPS of $6.12 versus $4.26 consensus and revenue of $5.63B versus $5.44B highlight clear upside from higher-acuity services and tight cost control.
  • Management lifted FY26 guidance to adjusted EPS of $20.30–$21.69 and revenue of $21.9B–$22.5B, with sizable bumps to EBITDA and free cash flow expectations.
  • Share repurchase authorization grew by $2.0B, leaving $2.13B available after $1.04B was bought back last quarter, signaling strong confidence in valuation.
  • Major banks including Wells Fargo, Barclays, Guggenheim, and BofA keep positive ratings on Tenet Healthcare, even while noting sector risks around payor mix and Medicaid.

Candlestick Chart

Weekly Update Jul 20 – Jul 24, 2026: On Friday, July 24, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 17.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Tenet Healthcare is executing from a position of clear strength in the hospital and ambulatory services space, with Q1 EBIT margin of ~24% and EBITDA margin of ~29% far above typical hospital peers in the mid-teens. Revenue growth (~14% three‑year CAGR) and robust FCF ($1.46B in the quarter; P/FCF ~2.5x) underscore a highly cash‑generative model. ROE near 40% and ROIC in the low‑ to mid‑teens offset elevated leverage (total debt/equity 2.7x, LT debt/capital 73%), which remains the main structural risk.

Technically, THC is in a powerful upside breakout. The stock vaulted from ~$196 to an intraday high near $233 with a large weekly range expansion and strong 5‑minute volume confirming institutional participation. The dominant trend is firmly bullish, with former resistance at ~$225–227 now the key near‑term support zone. An actionable level is buying pullbacks toward $225 with a stop below $215 and upside potential into the $240–245 area as momentum follows through.

Fundamentally and versus Healthcare and Providers & Services benchmarks, THC now screens as a top‑tier compounder: low‑9x P/E on raised FY26 EPS guidance ($20.30–21.69), mid‑20s EBITDA margins, and sector‑leading FCF, amplified by an additional $2B buyback authorization. Sell‑side targets clustering around $230–242 look conservative after the Q2 beat and guidance hike; a 12–14x EPS multiple supports a 12‑month target range of $245–275. Maintain a decisive Overweight bias while monitoring payor‑mix and Medicaid risk.

Quick Financial Overview

Tenet Healthcare Corporation (THC) just delivered the kind of quarter momentum traders look for. Q2 2026 adjusted EPS hit $6.12, not only well above last year’s $4.02 but also far ahead of the $4.26 consensus, on revenue of $5.63B versus $5.44B expected. That strength lines up with the broader income statement, where recent revenue runs at about $21.31B annually, supported by solid 14.13% three-year growth and strong gross margin of 82.1%.

Profitability metrics back the bullish narrative. THC shows EBIT margin of 18.6% and EBITDA margin of 22.8%, with total profit margin near 7.94%. Returns are high for a hospital operator, with return on equity near 48.5% and return on capital in the mid‑20s. Free cash flow is a standout: recent quarterly free cash flow was about $1.461B, with operating cash flow of $1.641B, easily funding capital spending and a heavy buyback program.

On valuation, a P/E around 9.21 and price-to-sales of 0.72 look lean given this growth profile, but leverage is not trivial. Total debt-to-equity of 2.74 and long‑term debt of about $13.128B keep balance‑sheet risk on the radar, even though interest coverage of 5.9 is adequate. Price action confirms the earnings reaction: the weekly close jumped from the mid‑$190s early in the week to $224.01, then printed $233.20 most recently, while intraday action shows a wide $233–$247 range with strong buying off the open and steady, controlled consolidation in the afternoon.

Conclusion

Tenet Healthcare Corporation has lined up strong fundamentals, bullish guidance, and constructive price action, which is exactly the mix short-term traders like to see. The Q2 2026 beat was not marginal; it was a clear upside surprise on both EPS and revenue, backed by better hospital margins and a push into higher-acuity services. Management then reinforced that strength by raising FY26 EPS guidance to $20.30–$21.69 and expanding free cash flow targets, while also adding $2.0B to the buyback authorization.

On the tape, THC ripped from the high‑$190s into the $230s, with intraday prints showing heavy volume and wide ranges near the open before tightening into a controlled up‑trend. That kind of move often attracts breakout and momentum traders, but it also means the stock can be stretched in the short term and prone to sharp pullbacks. Key risk remains sector‑wide: payor‑mix concerns and Medicaid uncertainty are weighing on multiples, as seen in modest price‑target trims from some banks even as they maintain Buy ratings.

For traders, the setup around Tenet Healthcare Corporation now is about balancing strong earnings momentum and buyback support against leverage and reimbursement risk. The key levels are the recent intraday highs in the mid‑$240s as resistance and the post‑earnings gap zone in the low‑$220s as an initial support area to watch. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” In other words, waiting for clean confirmations at those levels and avoiding emotional chasing is crucial when price is extended after a strong move. As I tell my students, “You do not get paid for believing the story, you get paid for trading the levels that the story creates.” This article is for educational and research purposes only.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?



Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”